Alzheimer’s disease: Clinical trials and drug development

Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide

Haass, C., & Selkoe, D. J. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2101 · Cited by 4,744 · see citing works

Network pharmacology: the next paradigm in drug discovery

Hopkins, A. L. (2008) · Nature Chemical Biology · doi:10.1038/nchembio.118 · Cited by 4,622 · see citing works

Alzheimer’s disease

Querfurth, H. W., & LaFerla, F. M. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0909142 · Cited by 4,569 · see citing works

Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria

Dubois, B., Feldman, H. H., Jacova, C., DeKosky, S. T., Barberger-Gateau, P., Cummings, J., Delacourte, A., Galasko, D., Gauthier, S., Jicha, G., et al. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70178-3 · Cited by 4,411 · see citing works

Amyloid-β protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory

Shankar, G. M., Li, S., Mehta, T. H., Garcia-Munoz, A., Shepardson, N. E., Smith, I., Brett, F. M., Farrell, M. A., Rowan, M. J., Lemere, C. A., et al. (2008) · Nature Medicine · doi:10.1038/nm1782 · Cited by 3,685 · see citing works

Mortality in Randomized Trials of Antioxidant Supplements for Primary and Secondary Prevention: Systematic Review and Meta-analysis

Bjelakovic, G., Nikolova, D., Gluud, L. L., Simonetti, R. G., & Gluud, C. (2007) · JAMA · doi:10.1001/jama.297.8.842 · Cited by 2,275 · see citing works

Memantine in Moderate-to-Severe Alzheimer's Disease

Reisberg, B., Doody, R., Stöffler, A., Schmitt, F., Ferris, S., & Möbius, H. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa013128 · Cited by 2,043 · see citing works

Cholinesterase inhibitors for Alzheimer's disease

Birks, J. S. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005593 · Cited by 1,906 · see citing works

Reducing Endogenous Tau Ameliorates Amyloid ß-Induced Deficits in an Alzheimer's Disease Mouse Model

Roberson, E. D., Scearce-Levie, K., Palop, J. J., Yan, F., Cheng, I. H., Wu, T., Gerstein, H., Yu, G.-Q., & Mucke, L. (2007) · Science · doi:10.1126/science.1141736 · Cited by 1,892 · see citing works

Cellular prion protein mediates impairment of synaptic plasticity by amyloid-β oligomers

Laurén, J., Gimbel, D. A., Nygaard, H. B., Gilbert, J. W., & Strittmatter, S. M. (2009) · Nature · doi:10.1038/nature07761 · Cited by 1,560 · see citing works

Long-term effects of Aβ42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial

Holmes, C., Boche, D., Wilkinson, D., Yadegarfar, G., Hopkins, V., Bayer, A., Jones, R. W., Bullock, R., Love, S., Neal, J. W., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61075-2 · Cited by 1,416 · see citing works

Memantine Treatment in Patients With Moderate to Severe Alzheimer Disease Already Receiving Donepezil: A Randomized Controlled Trial

Tariot, P. N., Farlow, M. R., Grossberg, G. T., Graham, S. M., McDonald, S., Gergel, I., & for the Memantine Study Group (2004) · JAMA · doi:10.1001/jama.291.3.317 · Cited by 1,403 · see citing works

Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial

Gilman, S., Koller, M., Black, R. S., Jenkins, L., Griffith, S. G., Fox, N. C., Eisner, L., Kirby, L., Rovira, M. B., Forette, F., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000159740.16984.3c · Cited by 1,329 · see citing works

A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease

Tuszynski, M. H., Thal, L., Pay, M., Salmon, D. P., U, H. S., Bakay, R., Patel, P., Blesch, A., Vahlsing, H. L., Ho, G., et al. (2005) · Nature Medicine · doi:10.1038/nm1239 · Cited by 1,050 · see citing works

Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's disease

Nagahara, A. H., Merrill, D. A., Coppola, G., Tsukada, S., Schroeder, B. E., Shaked, G. M., Wang, L., Blesch, A., Kim, A., Conner, J. M., et al. (2009) · Nature Medicine · doi:10.1038/nm.1912 · Cited by 1,034 · see citing works

Amyloid beta, mitochondrial dysfunction and synaptic damage: Implications for cognitive decline in aging and Alzheimer’s disease

Reddy, P. H., & Beal, M. F. (2008) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2007.12.002 · Cited by 975 · see citing works

Brain-derived neurotrophic factor in neurodegenerative diseases

Zuccato, C., & Cattaneo, E. (2009) · Nature Reviews Neurology · doi:10.1038/nrneurol.2009.54 · Cited by 947 · see citing works

The neuropathology of probable Alzheimer disease and mild cognitive impairment

Schneider, J. A., Arvanitakis, Z., Leurgans, S. E., & Bennett, D. A. (2009) · Annals of Neurology · doi:10.1002/ana.21706 · Cited by 935 · see citing works

The amyloid hypothesis for Alzheimer’s disease: A critical reappraisal

Hardy, J. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06181.x · Cited by 814 · see citing works

A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease

Salloway, S., Sperling, R., Gilman, S., Fox, N. C., Blennow, K., Raskind, M., Sabbagh, M., Honig, L. S., Doody, R., van Dyck, C. H., et al. (2009) · Neurology · doi:10.1212/wnl.0b013e3181c67808 · Cited by 753 · see citing works

ω-3 Fatty Acid Treatment in 174 Patients With Mild to Moderate Alzheimer Disease: OmegAD Study: A Randomized Double-blind Trial

Freund-Levi, Y., Eriksdotter-Jönhagen, M., Cederholm, T., Basun, H., Faxén-Irving, G., Garlind, A., Vedin, I., Vessby, B., Wahlund, L.-O., & Palmblad, J. (2006) · Archives of Neurology · doi:10.1001/archneur.63.10.1402 · Cited by 751 · see citing works

Safety, efficacy, and biomarker findings of PBT2 in targeting Aβ as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial

Lannfelt, L., Blennow, K., Zetterberg, H., Batsman, S., Ames, D., Harrison, J., Masters, C. L., Targum, S., Bush, A. I., Murdoch, R., et al. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70167-4 · Cited by 725 · see citing works

The amyloid β-peptide is imported into mitochondria via the TOM import machinery and localized to mitochondrial cristae

Hansson Petersen, C. A., Alikhani, N., Behbahani, H., Wiehager, B., Pavlov, P. F., Alafuzoff, I., Leinonen, V., Ito, A., Winblad, B., Glaser, E., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806192105 · Cited by 693 · see citing works

Rapid Restoration of Cognition in Alzheimer's Transgenic Mice with 8-Hydroxy Quinoline Analogs Is Associated with Decreased Interstitial Aβ

Adlard, P. A., Cherny, R. A., Finkelstein, D. I., Gautier, E., Robb, E., Cortes, M., Volitakis, I., Liu, X., Smith, J. P., Perez, K., et al. (2008) · Neuron · doi:10.1016/j.neuron.2008.06.018 · Cited by 672 · see citing works

Effect of Tarenflurbil on Cognitive Decline and Activities of Daily Living in Patients With Mild Alzheimer Disease<subtitle>A Randomized Controlled Trial</subtitle>

Green, R. C. (2009) · JAMA · doi:10.1001/jama.2009.1866 · Cited by 643 · see citing works

The worldwide societal costs of dementia: Estimates for 2009

Wimo, A., Winblad, B. G., & Jönsson, L. (2010) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2010.01.010 · Cited by 628 · see citing works

Effects of Aβ immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease

Fox, N. C., Black, R. S., Gilman, S., Rossor, M. N., Griffith, S. G., Jenkins, L., & Koller, M. (2005) · Neurology · doi:10.1212/01.wnl.0000159743.08996.99 · Cited by 550 · see citing works

The Role of Metabolic Disorders in Alzheimer Disease and Vascular Dementia: Two Roads Converged

Craft, S. (2009) · Archives of Neurology · doi:10.1001/archneurol.2009.27 · Cited by 547 · see citing works

Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines.

Wischik, C. M., Edwards, P. C., Lai, R. Y., Roth, M., & Harrington, C. R. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.20.11213 · Cited by 547 · see citing works

Alzheimer's disease – do tauists and baptists finally shake hands?

Mudher, A. K., & Lovestone, S. (2002) · Trends in Neurosciences · doi:10.1016/s0166-2236(00)02031-2 · Cited by 512 · see citing works

Intracerebroventricular Infusion of Nerve Growth Factor in Three Patients with Alzheimer’s Disease

Jönhagen, M. E., Nordberg, A. K., Amberla, K., Bäckman, L., Ebendal, T., Meyerson, B. A., Olson, L., Seiger, Å., Shigeta, M., Theodorsson, E., et al. (1998) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000017069 · Cited by 472 · see citing works

Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study

Doody, R. S., Si, G., Sano, M. C., Thomas, R. G., Aisen, P. S. S., Бачурин, С. О., Seely, L., & Hung, D. S.-Y. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61074-0 · Cited by 460 · see citing works

Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe

Feldman, H. H., Doody, R. S., Kivipelto, M., Sparks, D. L., Waters, D. D., Jones, R. W., Schwam, E., Schindler, R., Hey-Hadavi, J., DeMicco, D. A., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181d6476a · Cited by 438 · see citing works

Vitamin E for Alzheimer's dementia and mild cognitive impairment

Farina, N., Llewellyn, D. J., Isaac, M. G. E. K. N., & Tabet, N. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002854.pub5 · Cited by 421 · see citing works

The effects of omega-3 fatty acids monotherapy in Alzheimer's disease and mild cognitive impairment: A preliminary randomized double-blind placebo-controlled study

Chiu, C.-C., Su, K., Cheng, T., Liu, H., Chang, C.-J., Dewey, M. E., Stewart, R. J., & Huang, S. (2008) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2008.05.015 · Cited by 407 · see citing works

Nicotinamide restores cognition in Alzheimer's disease transgenic mice via a mechanism involving sirtuin inhibition and selective reduction of Thr231-phosphotau

Green, K. N., Steffan, J. S., Martinez-Coria, H., Sun, X., Schreiber, S. S., Thompson, L. M., & LaFerla, F. M. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.3203-08.2008 · Cited by 404 · see citing works

Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled study

Winblad, B. G., Kilander, L., Eriksson, S., Minthon, L., Båtsman, S., Wetterholm, A.-L., Jansson-Blixt, C., & Haglund, A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68350-5 · Cited by 388 · see citing works

Reassessing the amyloid cascade hypothesis of Alzheimer's disease

Pimplikar, S. W. (2008) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2008.12.015 · Cited by 373 · see citing works

Phospholipase A2 reduction ameliorates cognitive deficits in a mouse model of Alzheimer's disease

Sanchez-Mejia, R. O., Newman, J. W. I., Toh, S., Yu, G.-Q., Zhou, Y., Halabisky, B., Cissé, M., Scearce-Levie, K. A., Cheng, I. H.-J., Gan, L., et al. (2008) · Nature Neuroscience · doi:10.1038/nn.2213 · Cited by 369 · see citing works

A novel GSK-3β inhibitor reduces Alzheimer's pathology and rescues neuronal loss in vivo

Serenó, L., Coma, M., Rodríguez, M., Sánchez-Ferrer, P., Sánchez, M. B., Gich, I., Agulló, J. M., Pérez, M., Avila, J., Guardia-Laguarta, C., et al. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.05.025 · Cited by 368 · see citing works

Cyclohexanehexol inhibitors of Aβ aggregation prevent and reverse Alzheimer phenotype in a mouse model

McLaurin, J., Kierstead, M. E., Brown, M. E., Hawkes, C. A., Lambermon, M. H. L., Phinney, A. L., Darabie, A. A., Cousins, J. E., French, J. E., Lan, M. F., et al. (2006) · Nature Medicine · doi:10.1038/nm1423 · Cited by 366 · see citing works

Can Alzheimer disease be prevented by amyloid-β immunotherapy?

Lemere, C. A., & Masliah, E. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2009.219 · Cited by 351 · see citing works

Therapeutic effects of PKC activators in Alzheimer's disease transgenic mice

Etcheberrigaray, R., Tan, M., Dewachter, I., Kuipéri, C., der Auwera, I. V., Wera, S., Qiao, L., Bank, B., Nelson, T. J., Kozikowski, A. P., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0403921101 · Cited by 343 · see citing works

Immunosenescence: what does it mean to health outcomes in older adults?

McElhaney, J. E., & Effros, R. B. (2009) · Current Opinion in Immunology · doi:10.1016/j.coi.2009.05.023 · Cited by 340 · see citing works

Nerve growth factor affects11C-nicotine binding, blood flow, EEG, and verbal episodic memory in an Alzheimer patient (Case Report)

Olson, L., Nordberg, A. K., von Holst, H., Bäckman, L., Ebendal, T., Alafuzoff, I. I., Amberla, K., Hartvig, P., Herlitz, A., Lilja, A., et al. (1992) · Journal of Neural Transmission - Parkinsons Disease and Dementia Section · doi:10.1007/bf02257624 · Cited by 323 · see citing works

A γ‐secretase inhibitor decreases amyloid‐β production in the central nervous system

Bateman, R. J., Siemers, E. R., Mawuenyega, K. G., Wen, G., Browning, K. R., Sigurdson, W. C., Yarasheski, K. E., Friedrich, S. W., DeMattos, R. B., May, P. C., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21623 · Cited by 322 · see citing works

Intravenous immunoglobulins containing antibodies against -amyloid for the treatment of Alzheimer's disease

Dodel, R. C. (2004) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2003.033399 · Cited by 317 · see citing works

18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease

Relkin, N. R., Szabo, P., Adamiak, B., Burgut, T., Monthé, C., Lent, R. W., Younkin, S. G., Younkin, L. H., Schiff, R. I., & Weksler, M. E. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.12.021 · Cited by 305 · see citing works

Lithium trial in Alzheimer's disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study.

Hampel, H. J., Ewers, M., Bürger, K., Annas, P., Mörtberg, A., Bogstedt, A., Frölich, L., Schröder, J., Schönknecht, P., Riepe, M. W., et al. (2009) · PubMed · Cited by 305 · see citing works

Lithium Trial in Alzheimer's Disease

Hampel, H. J., Ewers, M., Bürger, K., Annas, P., Mörtberg, A., Bogstedt, A., Frölich, L., Schröder, J., Schönknecht, P., Riepe, M. W., et al. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04606 · Cited by 297 · see citing works

Minocycline Attenuates Neuronal Cell Death and Improves Cognitive Impairment in Alzheimer's Disease Models

Choi, Y., Kim, H., Shin, K. Y., Kim, E., Kim, M., Kim, H.-S., Park, C. H., Jeong, Y. H., Yoo, J., Lee, J., et al. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301377 · Cited by 290 · see citing works

Development of tau aggregation inhibitors for alzheimer's disease

Bulic, B., Pickhardt, M., Schmidt, B., Mandelkow, E., Waldmann, H., & Mandelkow, E. (2009) · Angewandte Chemie International Edition · doi:10.1002/anie.200802621 · Cited by 286 · see citing works

Degradation of the Alzheimer Disease Amyloid β-Peptide by Metal-dependent Up-regulation of Metalloprotease Activity

White, A. R., Du, T., Laughton, K. M., Volitakis, I., Sharples, R. A., Xilinas, M. E., Hoke, D. E., Holsinger, R. M. D., Evin, G., Cherny, R. A., et al. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m602487200 · Cited by 284 · see citing works

PPARγ Agonists as Therapeutics for the Treatment of Alzheimer's Disease

Landreth, G. E., Jiang, Q., Mandrekar, S., & Heneka, M. T. (2008) · Neurotherapeutics · doi:10.1016/j.nurt.2008.05.003 · Cited by 277 · see citing works

Substrate-targeting γ-secretase modulators

Kukar, T. L., Ladd, T. B., Bann, M. A., Fraering, P. C., Narlawar, R., Maharvi, G. M., Healy, B., Chapman, R., Welzel, A. T., Price, R. W., et al. (2008) · Nature · doi:10.1038/nature07055 · Cited by 276 · see citing works

Cellular prion protein regulates β-secretase cleavage of the Alzheimer's amyloid precursor protein

Parkin, E. T., Watt, N. T., Hussain, I., Eckman, E. A., Eckman, C. B., Manson, J. C., Baybutt, H. N., Turner, A. J., & Hooper, N. M. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0609621104 · Cited by 274 · see citing works

Methylene Blue Delays Cellular Senescence and Enhances Key Mitochondrial Biochemical Pathways

Atamna, H., Nguyen, A., Schultz, C., Boyle, K., Newberry, J., Kato, H., & Ames, B. N. (2008) · The FASEB Journal · doi:10.1096/fj.07-9610com · Cited by 272 · see citing works

Long-Term Follow-Up of Patients Immunized with AN1792: Reduced Functional Decline in Antibody Responders

Vellas, B. J., Black, R. S., Thal, L. J., Fox, N. C., Daniels, M., McLennan, G., Tompkins, C., Leibman, C. W., Pomfret, M., & Grundman, M. (2009) · Current Alzheimer Research · doi:10.2174/156720509787602852 · Cited by 256 · see citing works

Memantine in Moderate to Severe Alzheimer’s Disease: a Meta-Analysis of Randomised Clinical Trials

Winblad, B. G., Jones, R. W., Wirth, Y., Stöffler, A., & Möbius, H. J. (2007) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000102568 · Cited by 253 · see citing works

Clearance mechanisms of Alzheimer's amyloid-β peptide: implications for therapeutic design and diagnostic tests

Bates, K. A., Verdile, G., Li, Q.-X., Ames, D., Hudson, P., Masters, C. L., & Martins, R. N. (2009) · Molecular Psychiatry · doi:10.1038/mp.2008.96 · Cited by 247 · see citing works

Long-term course and effectiveness of combination therapy in Alzheimer disease

Atri, A., Shaughnessy, L. W., Locascio, J. J., & Growdon, J. H. (2008) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0b013e31816653bc · Cited by 230 · see citing works

AddNeuroMed—The European Collaboration for the Discovery of Novel Biomarkers for Alzheimer's Disease

Lovestone, S., Francis, P. T., Kłoszewska, I., Mecocci, P., Simmons, A., Soininen, H. S., Spenger, C., Tsolaki, M., Vellas, B. J., Wahlund, L., et al. (2009) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.05064.x · Cited by 211 · see citing works

Proteomic identification of brain proteins in the canine model of human aging following a long-term treatment with antioxidants and a program of behavioral enrichment: Relevance to Alzheimer's disease

Opii, W. O., Joshi, G., Head, E., Milgram, N. W., Muggenburg, B. A., Klein, J. B., Pierce, W. M., Cotman, C. W., & Butterfield, D. A. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.09.012 · Cited by 202 · see citing works

A Phase II study targeting amyloid-β with 3APS in mild-to-moderate Alzheimer disease

Aisen, P. S. S., Saumier, D., Briand, R., Laurin, J., Gervais, F., Tremblay, P. J., & Garceau, D. (2006) · Neurology · doi:10.1212/01.wnl.0000244346.08950.64 · Cited by 201 · see citing works

Omega‐3 supplementation in mild to moderate Alzheimer's disease: effects on neuropsychiatric symptoms

Freund‐Levi, Y., Basun, H., Cederholm, T., Irving, G. F., Garlind, A., Grut, M., Vedin, I., Palmblad, J. E. W., Wahlund, L., & Eriksdotter, M. (2007) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.1857 · Cited by 182 · see citing works

Liposomal vaccines with conformation-specific amyloid peptide antigens define immune response and efficacy in APP transgenic mice

Muhs, A., Hickman, D. T., Pihlgren, M., Chuard, N., Giriens, V., Meerschman, C., der Auwera, I. V., LEUVEN, F. V., Sugawara, M., Weingertner, M.-C., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0703137104 · Cited by 176 · see citing works

Novel Neuroprotective Mechanisms of Memantine: Increase in Neurotrophic Factor Release from Astroglia and Anti-Inflammation by Preventing Microglial Activation

Wu, H.-M., Tzeng, N., Li, Q., Wei, S., Hu, X., Chen, S., Rawls, S. M., Flood, P. M., Hong, J., & Lu, R. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2009.64 · Cited by 174 · see citing works

Cell Signaling Pathways and Iron Chelation in the Neurorestorative Activity of Green Tea Polyphenols: Special Reference to Epigallocatechin Gallate (EGCG)

Mandel, S. A., Amit, T., Kalfon, L., Reznichenko, L., Weinreb, O., & Youdim, M. B. H. (2008) · Journal of Alzheimer s Disease · doi:10.3233/jad-2008-15207 · Cited by 173 · see citing works

Mitochondria as a Target for Neurotoxins and Neuroprotective Agents

Бачурин, С. О., Shevtsova, E. F., Kireeva, E. G., Oxenkrug, G. F., & Sablin, S. O. (2003) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2003.tb07541.x · Cited by 169 · see citing works

Development of semagacestat (LY450139), a functional γ-secretase inhibitor, for the treatment of Alzheimer's disease

Henley, D. B., May, P. C., Dean, R. A., & Siemers, E. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560903044982 · Cited by 168 · see citing works

Generation of Aβ38 and Aβ42 Is Independently and Differentially Affected by Familial Alzheimer Disease-associated Presenilin Mutations and γ-Secretase Modulation

Page, R. M., Baumann, K., Tomioka, M., Pérez‐Revuelta, B. I., Fukumori, A., Jacobsen, H., Flohr, A., Luebbers, T., Ozmen, L., Steiner, H., et al. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m708754200 · Cited by 165 · see citing works

Intranasal NAP administration reduces accumulation of amyloid peptide and tau hyperphosphorylation in a transgenic mouse model of Alzheimer's disease at early pathological stage

Matsuoka, Y., Gray, A. J., Hirata‐Fukae, C., Minami, S., Waterhouse, E. G., Mattson, M. P., LaFerla, F. M., Gozes, I., & Aisen, P. S. S. (2007) · Journal of Molecular Neuroscience · doi:10.1385/jmn/31:02:165 · Cited by 161 · see citing works

Etazolate, a neuroprotective drug linking GABAA receptor pharmacology to amyloid precursor protein processing

Marcade, M., Bourdin, J., Loiseau, N., Peillon, H., Rayer, A., Drouin, D., Schweighoffer, F., & Désiré, L. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05396.x · Cited by 155 · see citing works

Current and future therapy in Alzheimer’s disease

van Marum, R. V. (2008) · Fundamental & Clinical Pharmacology · doi:10.1111/j.1472-8206.2008.00578.x · Cited by 151 · see citing works

Efficacy and safety of natural acetylcholinesterase inhibitor huperzine A in the treatment of Alzheimer’s disease: an updated meta-analysis

Wang, B.-S., Wang, H., Wei, Z.-H., Song, Y., Zhang, L., & Chen, H. (2009) · Journal of Neural Transmission · doi:10.1007/s00702-009-0189-x · Cited by 148 · see citing works

Secretase inhibitors and modulators for Alzheimer’s disease treatment

Tomita, T. (2009) · Expert Review of Neurotherapeutics · doi:10.1586/ern.09.24 · Cited by 146 · see citing works

Current Alzheimer's disease clinical trials: Methods and placebo outcomes

Schneider, L. S. S., & Sano, M. C. (2009) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2009.07.038 · Cited by 137 · see citing works

Mechanisms Behind the Neuroprotective Actions of Cholinesterase Inhibitors in Alzheimer Disease

Nordberg, A. K. (2006) · Alzheimer Disease & Associated Disorders · doi:10.1097/01.wad.0000213804.59187.2d · Cited by 134 · see citing works

Alzheimer's disease: new approaches to drug discovery

Bolognesi, M. L., Matera, R., Minarini, A., Rosini, M., & Melchiorre, C. (2009) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2009.04.619 · Cited by 132 · see citing works

Vitamin E for Alzheimer's disease and mild cognitive impairment

Isaac, M. G. E. K. N., Quinn, R., & Tabet, N. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002854.pub2 · Cited by 131 · see citing works

Development of AFFITOPE vaccines for Alzheimer's disease (AD) — From concept to clinical testing

Schneeberger, A., Mandler, M., Otava, O., Zauner, W., Mattner, F., & Schmidt, W. (2009) · The journal of nutrition health & aging · doi:10.1007/s12603-009-0070-5 · Cited by 130 · see citing works

Potential role of N-methyl-D-aspartate receptors as executors of neurodegeneration resulting from diverse insults: focus on memantine

Wenk, G. L., Parsons, C. G., & Danysz, W. (2006) · Behavioural Pharmacology · doi:10.1097/00008877-200609000-00007 · Cited by 128 · see citing works

Minocycline reduces the development of abnormal tau species in models of Alzheimer's disease

Noble, W., Garwood, C., Stephenson, J., Kinsey, A. M., Hanger, D., & Anderton, B. (2009) · The FASEB Journal · doi:10.1096/fj.08-113795 · Cited by 123 · see citing works

Hope in Alzheimer's fight emerges from unexpected places

Gura, T. (2008) · Nature Medicine · doi:10.1038/nm0908-894 · Cited by 123 · see citing works

Amyloid β-Peptide Promotes Permeability Transition Pore in Brain Mitochondria

Moreira, P. I., Santos, M. S., Moreno, A. J., & Oliveira, C. R. (2001) · Bioscience Reports · doi:10.1023/a:1015536808304 · Cited by 122 · see citing works

NAP protects memory, increases soluble tau and reduces tau hyperphosphorylation in a tauopathy model

Shiryaev, N., Jouroukhin, Y., Giladi, E., Polyzoidou, E., Grigoriadis, N., Rosenmann, H., & Gozes, I. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.02.011 · Cited by 122 · see citing works

Memoquin: A Multi-Target–Directed Ligand as an Innovative Therapeutic Opportunity for Alzheimer's Disease

Bolognesi, M. L., Cavalli, A., & Melchiorre, C. (2008) · Neurotherapeutics · doi:10.1016/j.nurt.2008.10.042 · Cited by 117 · see citing works

Double-Blind, Controlled Phase II Study of a 5-HT6 Receptor Antagonist, SB-742457, in Alzheimers Disease

Maher‐Edwards, G., Zvartau-Hind, M. E., Hunter, A. J., Gold, M., Hopton, G., Jacobs, G., Davy, M., & Williams, P. M. (2010) · Current Alzheimer Research · doi:10.2174/156720510791383831 · Cited by 117 · see citing works

Evaluation of Dimebon in cellular model of Huntington's disease

Wu, J., Li, Q., & Борисович, Б. И. (2008) · Molecular Neurodegeneration · doi:10.1186/1750-1326-3-15 · Cited by 117 · see citing works

Immunotherapy Targeting Pathological Tau Protein in Alzheimer's Disease and Related Tauopathies

Sigurdsson, E. M. (2008) · Journal of Alzheimer's Disease · doi:10.3233/jad-2008-15202 · Cited by 116 · see citing works

Treatment with the selective muscarinic ml agonist talsaclidine decreases cerebrospinal fluid levels of Aβ42in patients with Alzheimer's disease

Höck, C., Maddalena, A. S., Raschig, A., Müller-Spahn, F., Eschweiler, G. W., Huger, K., Hewer, I., Hampel, H. J., Müller-Thornsen, T., Oertel, W. H., et al. (2003) · Amyloid · doi:10.3109/13506120308995249 · Cited by 110 · see citing works

Multifunctional Neuroprotective Derivatives of Rasagiline as Anti-Alzheimer's Disease Drugs

Weinreb, O., Mandel, S. A., Bar‐Am, O., Yogev‐Falach, M., Avramovich‐Tirosh, Y., Amit, T., & Youdim, M. B. H. (2008) · Neurotherapeutics · doi:10.1016/j.nurt.2008.10.030 · Cited by 109 · see citing works

Delineating the Mechanism of Alzheimer’s Disease Aβ Peptide Neurotoxicity

Cappai, R., & Barnham, K. J. (2008) · Neurochemical Research · doi:10.1007/s11064-007-9469-8 · Cited by 108 · see citing works

Effect of a CYP2D6 polymorphism on the efficacy of donepezil in patients with Alzheimer disease

Pilotto, A., Franceschi, M., D’Onofrio, G., Bizzarro, A., Mangialasche, F., Cascavilla, L., Paris, F., Matera, M. G., Pilotto, A., Daniele, A., et al. (2009) · Neurology · doi:10.1212/wnl.0b013e3181b6bbe3 · Cited by 107 · see citing works

Methylthioninium chloride reverses cognitive deficits induced by scopolamine: comparison with rivastigmine

Deiana, S., Harrington, C. R., Wischik, C. M., & Riedel, G. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1394-2 · Cited by 106 · see citing works

Anti-Amyloid-β Immunotherapy in Alzheimer's Disease: Relevance of Transgenic Mouse Studies to Clinical Trials

Wilcock, D. M., & Colton, C. A. (2008) · Journal of Alzheimer s Disease · doi:10.3233/jad-2008-15404 · Cited by 106 · see citing works

Huperzine A protects isolated rat brain mitochondria against β-amyloid peptide

Gao, X., Zheng, C. Y., Yang, L., Tang, X. C., & Zhang, H. (2009) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2009.02.028 · Cited by 103 · see citing works

Pharmacological comparison of muscarinic ligands: Historical versus more recent muscarinic M1-preferring receptor agonists

Heinrich, J. N., Butera, J. A., Carrick, T. A., Kramer, A., Kowal, D. M., Lock, T., Marquis, K. L., Pausch, M. H., Popiolek, M., Sun, S.-C., et al. (2009) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.12.044 · Cited by 101 · see citing works

Effects of Omega-3 Fatty Acids on Inflammatory Markers in Cerebrospinal Fluid and Plasma in Alzheimer’s Disease: The OmegAD Study

Freund‐Levi, Y., Hjorth, E., Lindberg, C., Cederholm, T., Irving, G. F., Vedin, I., Palmblad, J. E. W., Wahlund, L., Schultzberg, M., Basun, H., et al. (2009) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000218081 · Cited by 100 · see citing works

Site-specific UBITh® amyloid-β vaccine for immunotherapy of Alzheimer's disease

Wang, C. Y., Finstad, C. L., Walfield, A. M., Sia, C., Sokoll, K. K., Chang, T.-Y., Fang, X. D., Hung, C. H., Hutter-Paier, B., & Windisch, M. (2007) · Vaccine · doi:10.1016/j.vaccine.2007.01.031 · Cited by 98 · see citing works

Towards Non Invasive Nerve Growth Factor Therapies for Alzheimer's Disease

Cattaneo, A., Capsoni, S., & Paoletti, F. (2008) · Journal of Alzheimer s Disease · doi:10.3233/jad-2008-15210 · Cited by 94 · see citing works

M1 Muscarinic Agonists Target Major Hallmarks of Alzheimer’s Disease – The Pivotal Role of Brain M1 Receptors

Fisher, A. (2008) · Neurodegenerative Diseases · doi:10.1159/000113712 · Cited by 87 · see citing works

CHF5074, a novel γ‐secretase modulator, attenuates brain β‐amyloid pathology and learning deficit in a mouse model of Alzheimer's disease

Imbimbo, B. P., Hutter‐Paier, B., Villetti, G., Facchinetti, F., Cenacchi, V., Volta, R., Lanzillotta, A., Pizzi, M., & Windisch, M. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2008.00097.x · Cited by 86 · see citing works

Back to the future: the 'old-fashioned' way to new medications for neurodegeneration

Lansbury, P. T. (2004) · Nature Medicine · doi:10.1038/nrn1435 · Cited by 86 · see citing works

Dimebon (Latrepirdine) Enhances Mitochondrial Function and Protects Neuronal Cells from Death

Zhang, S., Hedskog, L., Petersen, C. H., Winblad, B. G., & Ankarcrona, M. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-100174 · Cited by 85 · see citing works

Nogo receptor 1 regulates formation of lasting memories

Karlén, A., Karlsson, T. E., Mattsson, A., Lundströmer, K., Codeluppi, S., Pham, T. M., Bäckman, C. M., Ögren, S. O., Åberg, E., Hoffman, A. F., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0905390106 · Cited by 83 · see citing works

Effect of ispronicline, a neuronal nicotinic acetylcholine receptor partial agonist, in subjects with age associated memory impairment (AAMI)

Dunbar, G. C., Inglis, F., Kuchibhatla, R., Sharma, T., Tomlinson, M., & Wamsley, J. (2007) · Journal of Psychopharmacology · doi:10.1177/0269881107066855 · Cited by 75 · see citing works

Effects of memantine on cognition in patients with moderate to severe Alzheimer's disease: post‐hoc analyses of ADAS‐cog and SIB total and single‐item scores from six randomized, double‐blind, placebo‐controlled studies

Mecocci, P., Bladström, A., & Stender, K. (2009) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.2226 · Cited by 72 · see citing works

Analysis of microdissected human neurons by a sensitive ELISA reveals a correlation between elevated intracellular concentrations of Aβ42 and Alzheimer’s disease neuropathology

Hashimoto, M., Bogdanovic, N., Volkmann, I., Aoki, M., Winblad, B., & Tjernberg, L. O. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0661-6 · Cited by 69 · see citing works

Why Did Tarenflurbil Fail in Alzheimer's Disease?

Imbimbo, B. (2009) · Journal of Alzheimer's Disease · doi:10.3233/jad-2009-1092 · Cited by 66 · see citing works

The Quest for Small Molecules as Amyloid Inhibiting Therapies for Alzheimer's Disease

Amijee, H., & Scopes, D. I. C. (2009) · Journal of Alzheimer s Disease · doi:10.3233/jad-2009-1044 · Cited by 63 · see citing works

NAP and D-SAL: neuroprotection against the β amyloid peptide (1–42)

Gozes, I., Divinski, I., & Piltzer, I. (2008) · BMC Neuroscience · doi:10.1186/1471-2202-9-s3-s3 · Cited by 62 · see citing works

γ-Secretase: a complex target for Alzheimer's disease

Lundkvist, J., & Näslund, J. (2006) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2006.10.002 · Cited by 58 · see citing works

Alzheimers Disease Drug Development in 2008 and Beyond: Problems and Opportunities

Becker, R. E., & Greig, N. H. (2008) · Current Alzheimer Research · doi:10.2174/156720508785132299 · Cited by 55 · see citing works

Phenserine

Klein, J. (2007) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.16.7.1087 · Cited by 55 · see citing works

Can Lithium or Valproate Untie Tangles in Alzheimer's Disease?

Tariot, P. N., & Aisen, P. S. S. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.09com05331 · Cited by 53 · see citing works

Neurofibrillary degeneration in Alzheimer's disease: from molecular mechanisms to identification of drug targets

Pei, J.-J., Sjögren, M., & Winblad, B. (2008) · Current Opinion in Psychiatry · doi:10.1097/yco.0b013e328314b78b · Cited by 49 · see citing works

Immunotherapy against APP β-Secretase Cleavage Site Improves Cognitive Function and Reduces Neuroinflammation in Tg2576 Mice without a Significant Effect on Brain Aβ Levels

Rakover, I. S., Arbel, M., & Solomon, B. (2007) · Neurodegenerative Diseases · doi:10.1159/000103250 · Cited by 45 · see citing works

Amyloid‐beta reduction by memapsin 2 (beta‐secretase) immunization

Chang, W., Downs, D., Huang, X., Da, H., Fung, K.-M. A., & Tang, J. (2007) · The FASEB Journal · doi:10.1096/fj.06-7993com · Cited by 40 · see citing works

Review: Donepezil in Severe Alzheimer's Disease

Winblad, B. G. (2009) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.1177/1533317509332094 · Cited by 37 · see citing works

Cholesterol-modifying strategies for Alzheimer’s disease

Solomon, A., & Kivipelto, M. (2009) · Expert Review of Neurotherapeutics · doi:10.1586/ern.09.25 · Cited by 35 · see citing works

P4‐346: Safety, tolerability and biomarker effects of an Abeta monoclonal antibody administered to patients with Alzheimer's disease

Siemers, E., Friedrich, S. W., Dean, R. A., Sethuraman, G., Demattos, R. B., Jennings, D. L., Tamagnan, G. D., MAREK, K. L., & Seibyl, J. P. (2008) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2008.05.2416 · Cited by 32 · see citing works

O2‐05‐05: Results of the first‐in‐man study with the active Aβ Immunotherapy CAD106 in Alzheimer patients

Winblad, B. G., Minthon, L., Floesser, A., Imbert, G., Dumortier, T., He, Y., Maguire, P., Karlsson, M., Östlund, H., Lundmark, J., et al. (2009) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2009.05.356 · Cited by 32 · see citing works

Alzheimer's disease: γ-secretase inhibitors

Imbimbo, B. P. (2008) · Drug Discovery Today Therapeutic Strategies · doi:10.1016/j.ddstr.2008.10.002 · Cited by 31 · see citing works

Nogo Receptor Interacts with Brain APP and Aβ to Reduce Pathologic Changes in Alzheimers Transgenic Mice

Park, J. H., & Strittmatter, S. M. (2007) · Current Alzheimer Research · doi:10.2174/156720507783018235 · Cited by 30 · see citing works

Emerging and potential therapies for Alzheimer's disease

Jarosz-Griffiths, H., Morten, I. J., & Hooper, N. M. (2008) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.12.6.693 · Cited by 29 · see citing works

P2‐240: PF‐04447943, a novel PDE9A inhibitor, increases cGMP levels in cerebrospinal fluid: Translation from non‐clinical species to healthy human volunteers

Nicholas, T., Evans, R. M., Styren, S. D., Qiu, R., Wang, E. Q., Nelson, F., Le, V., Grimwood, S., Christoffersen, C. L., Banerjee, S., et al. (2009) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2009.04.553 · Cited by 25 · see citing works

Cortical Changes Following Spinal Cord Injury with Emphasis on the Nogo Signaling System

Endo, T., Tominaga, T., & Olson, L. (2009) · The Neuroscientist · doi:10.1177/1073858408329508 · Cited by 23 · see citing works

The Perils of Alzheimers Drug Development

Schneider, L. S. S., & Lahiri, D. K. (2009) · Current Alzheimer Research · doi:10.2174/156720509787313871 · Cited by 22 · see citing works

O2‐05‐03: Immunotherapy targeting abnormal protein conformation

Wısnıewskı, T., Prelli, F. C., Scholtzova, H., Chung, E., Mehta, P. D., Kascsak, R., Kascsak, R. J., & Goñi, F. (2009) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2009.05.354 · Cited by 20 · see citing works

O1‐04‐06: Effects of rosiglitazone as monotherapy in APOE4‐stratified subjects with mild‐to‐moderate Alzheimer's disease

Gold, M., Alderton, C., Zvartau-Hind, M. E., Ritchie, S. Y., Saunders, A. M., Craft, S., Landreth, G. E., Linnamägi, Ü., & Sawchak, S. T. (2009) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2009.05.219 · Cited by 18 · see citing works

P3‐254: Exebryl‐1: A novel small molecule currently in human clinical trials as a disease‐modifying drug for the treatment of Alzheimer's disease

Snow, A. D., Cummings, J. A., Lake, T. P., Hu, Q., Esposito, L., Cam, J. A., Hudson, M., Smith, E., & Runnels, S. (2009) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2009.04.925 · Cited by 18 · see citing works

P4‐348: Evp‐6124: Safety, Tolerability And Cognitive Effects Of A Novel A7 Nicotinic Receptor Agonist In Alzheimer's Disease Patients On Stable Donepezil Or Rivastigmine Therapy

Hilt, D. C., Gawryl, M. S., Koenig, G., & The EVP‐6124 Study Group (2009) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2009.07.147 · Cited by 18 · see citing works

P1‐279: NIC5‐15 as a treatment for Alzheimer's: Safety, pharmacokinetics and clinical variables

Grossman, H. T., Marzloff, G. E., Luo, X., LeRoith, D., Sano, M. C., & Pasinetti, G. M. (2009) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2009.04.287 · Cited by 17 · see citing works

O1‐04‐03: The ADCS valproate neuroprotection trial: Primary efficacy and safety results

Tariot, P. N., Aisen, P. S. S., Cummings, J. L., Jakimovich, L. J., Schneider, L. S. S., Thomas, R. G., Becerra, L. M., & Loy, R. (2009) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2009.05.216 · Cited by 16 · see citing works

P4‐351: Effects of uninterrrupted intravenous immunoglobulin treatment of Alzheimer's disease for nine months

Tsakanikas, D., Shah, K., Flores, C., Assuras, S., & Relkin, N. R. (2008) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2008.05.2422 · Cited by 14 · see citing works

P1‐268: Clinical trials of EHT 0202, a neuroprotective and procognitive alpha‐secretase stimulator for Alzheimer's disease

Désiré, L., Marcade, M., Peillon, H., Drouin, D., Sol, O., & Pando, M. (2009) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2009.04.276 · Cited by 14 · see citing works

O1‐04‐02: A clinical trial of docosahexanoic acid (DHA) for the treatment of Alzheimer's disease

Quinn, J. F., Raman, R., Thomas, R. G., Ernstrom, K. B., Yurko‐Mauro, K., Nelson, E. B., Shinto, L. H., Nair, A. K., & Aisen, P. S. S. (2009) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2009.05.215 · Cited by 14 · see citing works

P2‐375: Efficacy of the novel γ‐secretase inhibitor, PF‐3084014, in reducing Aβ in brain, CSF, and plasma in guinea pigs and Tg2576 mice

Wood, K. M., Lanz, T. A., Coffman, K. J., Becker, S. L., Deusen, J. V., Nolan, C. E., Richter, K. E. G., Finley, J. E., Brown, T. M., Brodney, M. A., et al. (2008) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2008.05.1453 · Cited by 13 · see citing works

P2‐377: A phase 2, double‐blind, placebo‐controlled study to evaluate the safety, tolerability, and effect on cognitive function of AL‐108 after 12 weeks of intranasal administration in subjects with mild cognitive impairment

Schmechel, D. E., Gerard, G., Vatakis, N. G., Harper, L., Ross, J., Bari, M. A., Walling, D. P., Stedman, M., Winston, J. L., Morimoto, B. H., et al. (2008) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2008.05.1455 · Cited by 13 · see citing works

O3‐06‐07: GSI‐953 is a potent APP‐selective gamma‐secretase inhibitor for the treatment of Alzheimer's disease

Jacobsen, S. J., Comery, T. A., Kreft, A. F., Mayer, S. C., Zaleska, M. M., Riddell, D. R., Bard, J., Gonzales, C., Frick, G. S., Raje, S., et al. (2009) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2009.05.472 · Cited by 12 · see citing works

O1‐04‐01: Results of the MIDAS trial: Effects of docosahexaenoic acid on physiological and safety parameters in age‐related cognitive decline

Yurko‐Mauro, K., McCarthy, D., Bailey‐Hall, E., Nelson, E. B., Blackwell, A. D., & MIDAS Investigators (2009) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2009.05.214 · Cited by 10 · see citing works

F1‐01‐04: Beta‐secretase as target for amyloid‐reduction therapy

Tang, J. (2009) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2009.05.177 · Cited by 10 · see citing works

Evaluation of β‐Alanine‐ and GABA‐Substituted Peptides as Inhibitors of Disease‐Linked Protein Aggregation

Madine, J., Wang, X., Brown, D. R., & Middleton, D. A. (2009) · ChemBioChem · doi:10.1002/cbic.200900219 · Cited by 10 · see citing works

P2‐213: Oral amyloid anti‐aggregating agent ELND005 is measurable in CSF and brain of healthy adult men

Garzone, P. D., Koller, M., Pastrak, A., Jhee, S. S., Ereshefsky, L., Moran, S., Cedarbaum, J. M., Xu, V., & Ross, B. D. (2009) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2009.04.526 · Cited by 10 · see citing works

P3‐243: The role for CSF dynabridging studies in developing new therapies for Alzheimer's disease

Ereshefsky, L., Jhee, S. S., Yen, M., & Moran, S. (2009) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2009.04.1016 · Cited by 9 · see citing works

F1‐01‐02: Rember: Issues in design of a phase 3 disease modifying clinical trial of Tau aggregation inhibitor therapy in Alzheimer's disease

Wischik, C. M. (2009) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2009.05.175 · Cited by 9 · see citing works

Double-Blind, Controlled Phase II Study of a 5-HT6 Receptor Antagonist, SB-742457, in Alzheimer's Disease

Maher‐Edwards, G., Zvartau-Hind, M. E., Hunter, A. J., Gold, M., Hopton, G., Jacobs, G., Davy, M., & Williams, P. M. (2010) · Current Alzheimer Research · doi:10.2174/1567210200438162050 · Cited by 9 · see citing works

P1‐259: Aβ variability and effect of gamma secretase inhibition on cerebrospinal fluid levels of Aβ in healthy volunteers

Soares, H. D., Raha, N., Sikpi, M. O., Liston, D. R., Brodney, M., Coffman, K. J., Tate, B. A., Qiu, R., Wang, E. Q., Li, X., et al. (2009) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2009.04.267 · Cited by 8 · see citing works

O4‐04‐03: Safety and pharmacokinetics of the anti‐amyloid monoclonal antibody PF‐04360365 following a single infusion in patients with mild‐to‐moderate Alzheimer's disease: Preliminary results

Bednar, M. M., Zhao, Q., Landen, J. W., Billing, C. B., Rohrbacher, K. D., & Kupiec, J. W. (2009) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2009.05.542 · Cited by 7 · see citing works

P1‐266: Disease progression analysis of ADAS‐cog from ADNI database in normal elderly, mild cognitive impairment and Alzheimer's disease patients

Ito, K., Corrigan, B., Zhao, Q., French, J. L., Miller, R., & Fullerton, T. (2009) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2009.04.274 · Cited by 7 · see citing works

P1‐254: A safety, tolerability and pharmacokinetic study of dimebon in patients with Alzheimer's disease already receiving donepezil

Tariot, P. N., Sabbagh, M. N., Flitman, S. S., Reyes, P. F., Taber, L., & Seely, L. (2009) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2009.04.262 · Cited by 7 · see citing works

P2‐221: ABT‐089, a neuronal nicotinic receptor partial agonist, reverses scopolamine‐induced cognitive deficits in healthy normal subjects

Baker, J. D., Lenz, R. A., Locke, C. S., Wesnes, K. A., Maruff, P. T., Abi‐Saab, W., & Saltarelli, M. D. (2009) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2009.04.534 · Cited by 6 · see citing works

[P‐167]: The Development of NIC5‐15, a natural anti‐diabetic agent, in the treatment of Alzheimer's disease

Wang, J., Ho, L., & Pasinetti, G. M. (2005) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2005.06.228 · Cited by 6 · see citing works

P2‐238: Modulation of catecholaminergic and cholinergic neurons in mice fed with LMN diet, rich in polyphenols and polyunsaturated fatty acids

Bolea, I., Valente, T., Hidalgo, J., Comes, G., Ramírez, B., Anglés, M. N., Morelló, J. R., Reguant, J., Boada, M., & Unzeta, M. (2009) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2009.04.551 · Cited by 5 · see citing works

P1‐258: Prediction of treatment response to rivastigmine in Parkinson's Disease Dementia

Adler, G., Bektas, M., Ko-Inoshishi, Y., Tracik, F. M., & The RIVAPARK Study Group (2009) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2009.04.266 · Cited by 4 · see citing works

P3‐242: The role of autophagy in potentially therapeutic copper complexes

Price, K. A., Lim, S. C., Patterson, B., Caragounis, A., Volitakis, I., Cherny, R. A., Masters, C. L., Barnham, K. J., Donnelly, P. S., Crouch, P. J., et al. (2009) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2009.04.1015 · Cited by 4 · see citing works

O1‐04‐04: A multicenter, double‐blind, placebo‐controlled phase IIb proof‐of‐concept dose‐ranging study of AZD3480 and donepezil over 12 weeks in patients with mild to moderate Alzheimer's disease

Frölich, L., Eckerwall, G., Jonas, N., & The Sirocco Investigators (2009) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2009.05.217 · Cited by 4 · see citing works

Untitled work

(2000) · doi:10.1002/1531-8249(200012)48:6

Neurovascular pathways to neurodegeneration in Alzheimer’s disease and other disorders

Zlokovic, B. V. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn3114 · Cited by 2,969 · see citing works

The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics

Karran, E., Mercken, M., & Strooper, B. D. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3505 · Cited by 2,188 · see citing works

ROS Generation in Microglia: Understanding Oxidative Stress and Inflammation in Neurodegenerative Disease

Simpson, D. S. A., & Oliver, P. L. (2020) · Antioxidants · doi:10.3390/antiox9080743 · Cited by 1,044 · see citing works

Brain atrophy in Alzheimer’s Disease and aging

Pini, L., Pievani, M., Bocchetta, M., Altomare, D., Bosco, P., Cavedo, E., Galluzzi, S., Marizzoni, M., & Frisoni, G. B. (2016) · Ageing Research Reviews · doi:10.1016/j.arr.2016.01.002 · Cited by 874 · see citing works

A systemic view of Alzheimer disease — insights from amyloid-β metabolism beyond the brain

Wang, J., Gu, B. J., Masters, C. L., & Wang, Y.-J. (2017) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.111 · Cited by 808 · see citing works

APP mouse models for Alzheimer’s disease preclinical studies.

Sasaguri, H., Nilsson, P., Hashimoto, S., Nagata, K., Saito, T., De Strooper, B., Hardy, J., Vassar, R., Winblad, B., & Saido, T. C. (2017) · The EMBO Journal · doi:10.15252/embj.201797397 · Cited by 793 · see citing works

BDNF-based synaptic repair as a disease-modifying strategy for neurodegenerative diseases

Lu, B., Nagappan, G., Guan, X.-M., Nathan, P. J., & Wren, P. B. (2013) · Nature reviews. Neuroscience · doi:10.1038/nrn3505 · Cited by 747 · see citing works

Amyloid Oligomers: A Joint Experimental/Computational Perspective on Alzheimer’s Disease, Parkinson’s Disease, Type II Diabetes, and Amyotrophic Lateral Sclerosis

Nguyen, P. H., Ramamoorthy, A., Sahoo, B. R., Zheng, J., Faller, P., Straub, J. E., Domı́nguez, L., Shea, J., Dokholyan, N. V., Simone, A. D., et al. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c01122 · Cited by 676 · see citing works

Clinical trials and late‐stage drug development for <scp>A</scp>lzheimer's disease: an appraisal from 1984 to 2014

Schneider, L. S., Mangialasche, F., Andreasen, N., Feldman, H., Giacobini, E., Jones, R., Mantua, V., Mecocci, P., Pani, L., Winblad, B., et al. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12191 · Cited by 651 · see citing works

The Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER): Study design and progress

Kivipelto, M., Solomon, A., Ahtiluoto, S., Ngandu, T., Lehtisalo, J., Antikainen, R., Bäckman, L., Hänninen, T., Jula, A., Laatikainen, T., et al. (2013) · Alzheimer's &amp; Dementia · doi:10.1016/j.jalz.2012.09.012 · Cited by 589 · see citing works

Amyloid cascade hypothesis: Pathogenesis and therapeutic strategies in Alzheimer's disease

Barage, S. H., & Sonawane, K. D. (2015) · Neuropeptides · doi:10.1016/j.npep.2015.06.008 · Cited by 579 · see citing works

Bidirectional relationship between sleep and Alzheimer’s disease: role of amyloid, tau, and other factors

Wang, C., & Holtzman, D. M. (2019) · Neuropsychopharmacology · doi:10.1038/s41386-019-0478-5 · Cited by 589 · see citing works

Energy metabolism and inflammation in brain aging and Alzheimer’s disease

Yin, F., Sancheti, H., Patil, I., & Cadenas, E. (2016) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2016.04.200 · Cited by 538 · see citing works

Screening out irrelevant cell-based models of disease

Horvath, P., Aulner, N., Bickle, M., Davies, A. M., Nery, E. D., Ebner, D., Montoya, M. C., Östling, P., Pietiäinen, V., Price, L. S., et al. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.175 · Cited by 525 · see citing works

Current Developments of Coumarin Compounds in Medicinal Chemistry

Peng, X.-M., Damu, G. L. V., & Zhou, C. H. (2013) · Current Pharmaceutical Design · doi:10.2174/1381612811319210013 · Cited by 507 · see citing works

Scanning ultrasound removes amyloid-β and restores memory in an Alzheimer’s disease mouse model

Leinenga, G., & Götz, J. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa2512 · Cited by 498 · see citing works

The amyloid cascade-inflammatory hypothesis of Alzheimer disease: implications for therapy

McGeer, P. L., & McGeer, E. G. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1177-7 · Cited by 467 · see citing works

Deep learning to detect Alzheimer's disease from neuroimaging: A systematic literature review

Ghahnavieh, A. E., Luo, S., & Chiong, R. (2019) · Computer Methods and Programs in Biomedicine · doi:10.1016/j.cmpb.2019.105242 · Cited by 439 · see citing works

Artificial intelligence and machine learning-aided drug discovery in central nervous system diseases: State-of-the-arts and future directions

Vatansever, S., Schlessinger, A., Wacker, D., Kaniskan, H. Ü., Jin, J., Zhou, M., & Zhang, B. (2021) · Medicinal Research Reviews · doi:10.1002/med.21764 · Cited by 429 · see citing works

Cognitive function in patients with diabetes mellitus: guidance for daily care

Koekkoek, P. S., Kappelle, L. J., van den Berg, E., Rutten, G. E. H. M., & Biessels, G. J. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70249-2 · Cited by 401 · see citing works

Recent advances in siRNA delivery mediated by lipid-based nanoparticles

Yonezawa, S., Koide, H., & Asai, T. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.07.022 · Cited by 386 · see citing works

Alzheimer's Disease and the Amyloid Cascade Hypothesis: A Critical Review

Reitz, C. (2012) · International Journal of Alzheimer s Disease · doi:10.1155/2012/369808 · Cited by 373 · see citing works

Microglia in the Neuroinflammatory Pathogenesis of Alzheimer’s Disease and Related Therapeutic Targets

Cai, Y., Liu, J., Wang, B., Sun, M., & Yang, H. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.856376 · Cited by 351 · see citing works

Comprehensive review of mechanisms of pathogenesis involved in Alzheimer’s disease and potential therapeutic strategies

Sharma, P., Srivastava, P., Seth, A., Tripathi, P. N., Banerjee, A. G., & Shrivastava, S. K. (2019) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2018.12.006 · Cited by 331 · see citing works

New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugs

Salomone, S., Caraci, F., Leggio, G. M., Fedotova, J., & Drago, F. (2011) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2011.04134.x · Cited by 322 · see citing works

Recent Advances in the Inhibition of p38 MAPK as a Potential Strategy for the Treatment of Alzheimer’s Disease

Lee, J. K., & Kim, N. (2017) · Molecules · doi:10.3390/molecules22081287 · Cited by 323 · see citing works

Mouse models of Alzheimer's disease

Hall, A. M., & Roberson, E. D. (2012) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2011.11.017 · Cited by 317 · see citing works

Tonic inhibition in dentate gyrus impairs long-term potentiation and memory in an Alzheimer’s disease model

Wu, Z., Guo, Z., Gearing, M., & Chen, G. (2014) · Nature Communications · doi:10.1038/ncomms5159 · Cited by 306 · see citing works

Drugs in Clinical Trials for Alzheimer's Disease: The Major Trends

Бачурин, С. О., Bovina, E. V., & Ustyugov, A. A. (2017) · Medicinal Research Reviews · doi:10.1002/med.21434 · Cited by 305 · see citing works

Drug repositioning for Alzheimer's disease

Corbett, A., Pickett, J., Burns, A. S., Corcoran, J. P. T., Dunnett, S. B., Edison, P., Hagan, J. J., Holmes, C., Jones, E., Katona, C., et al. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3869 · Cited by 302 · see citing works

Prevention of sporadic Alzheimer's disease: lessons learned from clinical trials and future directions

Andrieu, S., Coley, N., Lovestone, S., Aisen, P. S., & Vellas, B. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00153-2 · Cited by 293 · see citing works

Exercise counteracts declining hippocampal function in aging and Alzheimer's disease

Intlekofer, K. A., & Cotman, C. W. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2012.06.011 · Cited by 286 · see citing works

Neuroprotective and Anti-Aging Potentials of Essential Oils from Aromatic and Medicinal Plants

Ayaz, M., Sadiq, A., Junaid, M., Ullah, F., Subhan, F., & Ahmed, J. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00168 · Cited by 287 · see citing works

A critique of the drug discovery and phase 3 clinical programs targeting the amyloid hypothesis for Alzheimer disease

Karran, E. H., & Hardy, J. (2014) · Annals of Neurology · doi:10.1002/ana.24188 · Cited by 275 · see citing works

Novel advances in shotgun lipidomics for biology and medicine

Wang, M., Wang, C., Han, R. H., & Han, X. (2015) · Progress in Lipid Research · doi:10.1016/j.plipres.2015.12.002 · Cited by 269 · see citing works

Bioactive metabolites from macrofungi: ethnopharmacology, biological activities and chemistry

Silva, D. D. D., Rapior, S., Sudarman, E., Stadler, M., Xu, J., Alias, S. A., & Hyde, K. D. (2013) · Fungal Diversity · doi:10.1007/s13225-013-0265-2 · Cited by 271 · see citing works

Antioxidant clinical trials in mild cognitive impairment and Alzheimer's disease

Mecocci, P., & Polidori, M. C. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2011.10.006 · Cited by 270 · see citing works

Immunotherapy for Alzheimer’s disease: targeting β-amyloid and beyond

Song, C., Shi, J., Zhang, P., Zhang, Y., Xu, J., Zhao, L., Zhang, R., Wang, H., & Chen, H. (2022) · Translational Neurodegeneration · doi:10.1186/s40035-022-00292-3 · Cited by 266 · see citing works

Tau-aggregation inhibitor therapy for Alzheimer's disease

Wischik, C. M., Harrington, C. R., & Storey, J. M. D. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.12.008 · Cited by 263 · see citing works

Frames and counter-frames giving meaning to dementia: A framing analysis of media content

Gorp, B. V., & Vercruysse, T. (2012) · Social Science & Medicine · doi:10.1016/j.socscimed.2011.12.045 · Cited by 253 · see citing works

Rodent models of neuroinflammation for Alzheimer’s disease

Nazem, A., Sankowski, R., Bacher, M., & Al‐Abed, Y. (2015) · Journal of Neuroinflammation · doi:10.1186/s12974-015-0291-y · Cited by 249 · see citing works

First-in-man tau vaccine targeting structural determinants essential for pathological tau–tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer’s disease model

Kontseková, E., Žilka, N., Kováčech, B., Novák, P., & Novák, M. (2014) · Alzheimer s Research & Therapy · doi:10.1186/alzrt278 · Cited by 248 · see citing works

Nrf2: a dark horse in Alzheimer's disease treatment

Osama, A., Zhang, J., Yao, J., Yao, X., & Fang, J. (2020) · Ageing Research Reviews · doi:10.1016/j.arr.2020.101206 · Cited by 251 · see citing works

In Vitro Screening for Anti-Cholinesterase and Antioxidant Activity of Methanolic Extracts of Ayurvedic Medicinal Plants Used for Cognitive Disorders

Mathew, M., & Subramanian, S. (2014) · PLoS ONE · doi:10.1371/journal.pone.0086804 · Cited by 237 · see citing works

Transcriptional data: a new gateway to drug repositioning?

Iorio, F., Rittman, T., Ge, H., Menden, M. P., & Sáez-Rodríguez, J. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2012.07.014 · Cited by 237 · see citing works

Current and Emerging Drug Treatment Options for Alzheimerʼs Disease

Herrmann, N., Chau, S. A., Kircanski, I., & Lanctôt, K. L. (2011) · Drugs · doi:10.2165/11595870-000000000-00000 · Cited by 238 · see citing works

The future of Alzheimer's disease: The next 10 years

Hampel, H. J., Prvulovic, D., Teipel, S. J., Jessen, F., Luckhaus, C., Frölich, L., Riepe, M. W., Dodel, R. C., Leyhe, T., Bertram, L., et al. (2011) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2011.11.008 · Cited by 233 · see citing works

Multivariate Data Analysis and Machine Learning in Alzheimer's Disease with a Focus on Structural Magnetic Resonance Imaging

Falahati, F., Westman, E., & Simmons, A. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-131928 · Cited by 229 · see citing works

In vivo Evidence for Therapeutic Properties of Cannabidiol (CBD) for Alzheimer's Disease

Watt, G., & Karl, T. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00020 · Cited by 227 · see citing works

Nanotechnology-based drug delivery systems for Alzheimer's disease management: Technical, industrial, and clinical challenges

Wen, M. M., El-Salamouni, N. S., El-Refaie, W. M., Hazzah, H. A., Ali, M. M., Tosi, G., Farid, R. M., Blanco‐Prieto, M. J., Billa, N., & Hanafy, A. S. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.11.025 · Cited by 225 · see citing works

Modulation of neurotrophic signaling pathways by polyphenols

Firuzi, O., Moosavi, F., Hosseini, R., & Saso, L. (2015) · Drug Design Development and Therapy · doi:10.2147/dddt.s96936 · Cited by 224 · see citing works

Chemical Kinetics for Bridging Molecular Mechanisms and Macroscopic Measurements of Amyloid Fibril Formation

Michaels, T. C. T., Šarić, A., Habchi, J., Chia, S., Meisl, G., Vendruscolo, M., Dobson, C. M., & Knowles, T. P. J. (2018) · Annual Review of Physical Chemistry · doi:10.1146/annurev-physchem-050317-021322 · Cited by 215 · see citing works

Anti-Alzheimer’s Studies on β-Sitosterol Isolated from Polygonum hydropiper L.

Ayaz, M., Junaid, M., Ullah, F., Subhan, F., Sadiq, A., Ali, G., Ovais, M., Shahid, M., Ahmad, A., Wadood, A., et al. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00697 · Cited by 220 · see citing works

Early-Onset Familial Alzheimer's Disease (EOFAD)

Wu, L., Rosa‐Neto, P., Hsiung, G. R., Sadovnick, A. D., Masellis, M., Black, S. E., Jia, J., & Gauthier, S. G. (2012) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100013949 · Cited by 218 · see citing works

Alkaloids as a source of potential anticholinesterase inhibitors for the treatment of Alzheimer's disease

Konrath, E. L., Passos, C. D. S., Klein‐Júnior, L. C., & Henriques, A. T. (2013) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.12090 · Cited by 219 · see citing works

Newly developed reversible MAO-B inhibitor circumvents the shortcomings of irreversible inhibitors in Alzheimer’s disease

Park, J.-H., Ju, Y. H., Choi, J. W., Song, H. J., Jang, B. K., Woo, J., Chun, H., Kim, H. J., Shin, S. J., Yarishkin, O., et al. (2019) · Science Advances · doi:10.1126/sciadv.aav0316 · Cited by 216 · see citing works

Causal machine learning for healthcare and precision medicine

Sanchez, P., Voisey, J. P., Xia, T., Watson, H. I., O’Neil, A. Q., & Tsaftaris, S. A. (2022) · Royal Society Open Science · doi:10.1098/rsos.220638 · Cited by 225 · see citing works

The main cost drivers in dementia: a systematic review: Systematic review of COI studies in dementia focusing on care settings

Schaller, S., Mauskopf, J., Kriza, C., Wahlster, P., & Kolominsky-Rabas, P. L. (2015) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.4198 · Cited by 215 · see citing works

Alzheimer's therapeutics: Continued clinical failures question the validity of the amyloid hypothesis—but what lies beyond?

Mullane, K., & Williams, M. J. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.11.014 · Cited by 212 · see citing works

Mitochondrial Dysfunction: a Potential Therapeutic Target to Treat Alzheimer’s Disease

Nand, S., Singh, C., Singh, A., Singh, M. P., & Singh, S. P. (2020) · Molecular Neurobiology · doi:10.1007/s12035-020-01945-y · Cited by 213 · see citing works

Regulation of Copper and Iron Homeostasis by Metal Chelators: A Possible Chemotherapy for Alzheimer’s Disease

Robert, A., Liu, Y., Nguyen, M., & Meunier, B. (2015) · Accounts of Chemical Research · doi:10.1021/acs.accounts.5b00119 · Cited by 212 · see citing works

Noncoding RNAs in Alzheimer's disease

Idda, M. L., Munk, R. B., Abdelmohsen, K., & Gorospe, M. (2018) · Wiley Interdisciplinary Reviews - RNA · doi:10.1002/wrna.1463 · Cited by 206 · see citing works

Development of interventions for the secondary prevention of Alzheimer's dementia: the European Prevention of Alzheimer's Dementia (EPAD) project

Ritchie, C. W., Molinuevo, J. L., Truyen, L., Satlin, A., der Geyten, S. V., & Lovestone, S. (2015) · The Lancet Psychiatry · doi:10.1016/s2215-0366(15)00454-x · Cited by 202 · see citing works

Multi-Target-Directed Ligands and other Therapeutic Strategies in the Search of a Real Solution for Alzheimer’s Disease

Agis-Torres, A., Sollhuber, M., Fernandez, M., & Sanchez-Montero, J. M. (2014) · Current Neuropharmacology · doi:10.2174/1570159x113116660047 · Cited by 202 · see citing works

Current treatment options for Alzheimer’s disease and Parkinson’s disease dementia

Y.Y. Szeto, J., & J.G. Lewis, S. (2016) · Current Neuropharmacology · doi:10.2174/1570159x14666151208112754 · Cited by 198 · see citing works

Network Dysfunction in Alzheimer's Disease: Refining the Disconnection Hypothesis

Brier, M. R., Thomas, J., & Ances, B. M. (2014) · Brain Connectivity · doi:10.1089/brain.2014.0236 · Cited by 192 · see citing works

Life Extension Factor Klotho Prevents Mortality and Enhances Cognition in hAPP Transgenic Mice

Dubal, D. B., Zhu, L., Sanchez, P. E., Worden, K., Broestl, L., Johnson, E. C. B., Ho, K., Yu, G.-Q., Kim, D., Bétourné, A., et al. (2015) · Journal of Neuroscience · doi:10.1523/jneurosci.5791-12.2015 · Cited by 192 · see citing works

Mild Cognitive Impairment: Diagnosis, Longitudinal Course, and Emerging Treatments

Vega, J. N., & NEWHOUSE, P. A. (2014) · Current Psychiatry Reports · doi:10.1007/s11920-014-0490-8 · Cited by 196 · see citing works

Inhibition of AMP-activated protein kinase signaling alleviates impairments in hippocampal synaptic plasticity induced by amyloid β

Ma, T., Chen, Y., Vingtdeux, V., Zhao, H., Viollet, B., Marambaud, P., & Klann, E. (2014) · The Journal of Neuroscience · doi:10.1523/jneurosci.1694-14.2014 · Cited by 191 · see citing works

Epidermal growth factor receptor is a preferred target for treating Amyloid-β–induced memory loss

Wang, L., Chiang, H.-C., Wu, W., Liang, B., Xie, Z., Yao, X., Ma, W., Du, S., & Zhong, Y. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1208011109 · Cited by 190 · see citing works

Biomaterial Scaffold Fabrication Techniques for Potential Tissue Engineering Applications

Subia, B., Kundu, S. C., & C., S. (2010) · InTech eBooks · doi:10.5772/8581 · Cited by 187 · see citing works

Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial

Dodel, R. C., Rominger, A., Bartenstein, P., Barkhof, F., Blennow, K., Förster, S., Winter, Y., Bach, J., Popp, J., Alferink, J., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70014-0 · Cited by 187 · see citing works

Understanding the Amyloid Hypothesis in Alzheimer’s Disease

Paroni, G., Bisceglia, P., & Seripa, D. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-180802 · Cited by 186 · see citing works

Oxidative Damage to RNA in Aging and Neurodegenerative Disorders

Nunomura, A., Moreira, P. I., Castellani, R. J., Lee, H., Zhu, X., Smith, M. A., & Perry, G. L. (2012) · Neurotoxicity Research · doi:10.1007/s12640-012-9331-x · Cited by 183 · see citing works

Neuroinflammation in Alzheimer’s disease; A source of heterogeneity and target for personalized therapy

Latta, C. H., Brothers, H. M., & Wilcock, D. M. (2014) · Neuroscience · doi:10.1016/j.neuroscience.2014.09.061 · Cited by 176 · see citing works

Anti-Aβ Drug Screening Platform Using Human iPS Cell-Derived Neurons for the Treatment of Alzheimer's Disease

Yahata, N., Asai, M., Kitaoka, S., Takahashi, K., Asaka, I., Hioki, H., Kaneko, T., Maruyama, K., Saido, T. C., Nakahata, T., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0025788 · Cited by 175 · see citing works

A brief overview of amyloids and Alzheimer's disease

Ow, S., & Dunstan, D. E. (2014) · Protein Science · doi:10.1002/pro.2524 · Cited by 178 · see citing works

Multi-Target Directed Drugs: A Modern Approach for Design of New Drugs for the treatment of Alzheimer’s Disease

Dias, K. S. T., & Viegas, C. (2014) · Current Neuropharmacology · doi:10.2174/1570159x1203140511153200 · Cited by 174 · see citing works

Cathepsin B in neurodegeneration of Alzheimer's disease, traumatic brain injury, and related brain disorders

HOOK, V. Y. H., Yoon, M. C., Mosier, C., Ito, G., Podvin, S., Head, B. P., Rissman, R. A., O’Donoghue, A. J., & Hook, G. (2020) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2020.140428 · Cited by 170 · see citing works

Comparative safety and effectiveness of cholinesterase inhibitors and memantine for Alzheimer’s disease: A network meta-analysis of 41 randomized controlled trials

Dou, K.-X., Tan, M.-S., Tan, C.-C., Cao, X.-P., Hou, X.-H., Guo, Q.-H., Tan, L., Mok, V., & Yu, J.-T. (2018) · Alzheimer's Research &amp; Therapy · doi:10.1186/s13195-018-0457-9 · Cited by 171 · see citing works

Secretase inhibitors for the treatment of Alzheimer's disease: Long road ahead

Kumar, D., Ganeshpurkar, A., Kumar, D., Modi, G. P., Gupta, S., & Singh, S. K. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.02.035 · Cited by 170 · see citing works

Human neural stem cells alleviate Alzheimer-like pathology in a mouse model

Lee, I.-S., Jung, K., Kim, I., Lee, H.-J., Kim, M., Yun, S., Hwang, K., Shin, J. E., & Park, K. I. (2015) · Molecular Neurodegeneration · doi:10.1186/s13024-015-0035-6 · Cited by 169 · see citing works

Microenvironment Remodeling Micelles for Alzheimer's Disease Therapy by Early Modulation of Activated Microglia

Lü, Y., Guo, Z., Zhang, Y., Li, C., Zhang, Y., Guo, Q., Chen, Q., Chen, X., He, X., Liu, L., et al. (2018) · Advanced Science · doi:10.1002/advs.201801586 · Cited by 162 · see citing works

Therapeutic approaches to Huntington disease: from the bench to the clinic

Caron, N. S., Dorsey, E. R., & Hayden, M. R. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.133 · Cited by 161 · see citing works

Neuroprotective Role of Phytochemicals

Velmurugan, B. K., Baskaran, R., Lohanathan, B. P., Thiyagarajan, V., & Weng, C. (2018) · Molecules · doi:10.3390/molecules23102485 · Cited by 163 · see citing works

Serotonin 5-HT6Receptor Antagonists for the Treatment of Cognitive Deficiency in Alzheimer’s Disease

Benhamú, B., Martín‐Fontecha, M., Vázquez‐Villa, H., Pardo, L., & López-Rodríguez, M. L. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm5003952 · Cited by 160 · see citing works

Design of LVFFARK and LVFFARK-Functionalized Nanoparticles for Inhibiting Amyloid β-Protein Fibrillation and Cytotoxicity

Xiong, N., Dong, X., Zheng, J., Liu, F., & Sun, Y. P. (2015) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.5b00915 · Cited by 158 · see citing works

Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases

Lleó, A., Cavedo, E., Parnetti, L., Vanderstichele, H., Herukka, S., Andreasen, N., Ghidoni, R., Lewczuk, P., Jeromin, A., Winblad, B. G., et al. (2014) · Nature Reviews Neurology · doi:10.1038/nrneurol.2014.232 · Cited by 159 · see citing works

MicroRNAs in Alzheimer's disease: Potential diagnostic markers and therapeutic targets

Liu, S., Fan, M., Zheng, Q., Hao, S., Yang, L., Xia, Q., Qi, C., & Ge, J. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.112681 · Cited by 156 · see citing works

Amyloid‐ß‐directed immunotherapy for Alzheimer's disease

Lannfelt, L., Relkin, N. R., & Siemers, E. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12168 · Cited by 157 · see citing works

Alzheimer's disease, enzyme targets and drug discovery struggles: From natural products to drug prototypes

Silva, T., Reis, J., Teixeira, J., & Borges, F. (2014) · Ageing Research Reviews · doi:10.1016/j.arr.2014.03.008 · Cited by 157 · see citing works

The Important Role of Zinc in Neurological Diseases

Li, Z., Liu, Y., Wei, R., Yong, V. W., & Xue, M. (2022) · Biomolecules · doi:10.3390/biom13010028 · Cited by 163 · see citing works

Targeting drugs to mitochondria

Heller, A., Brockhoff, G., & Göpferich, A. M. (2012) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2012.05.014 · Cited by 155 · see citing works

Effects of Home Photobiomodulation Treatments on Cognitive and Behavioral Function, Cerebral Perfusion, and Resting-State Functional Connectivity in Patients with Dementia: A Pilot Trial

Chao, L. L. (2019) · Photobiomodulation Photomedicine and Laser Surgery · doi:10.1089/photob.2018.4555 · Cited by 155 · see citing works

From mild cognitive impairment to subjective cognitive decline: conceptual and methodological evolution.

Cheng, Y.-W., Chen, T.-F., & Chiu, M.-J. (2017) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s123428 · Cited by 150 · see citing works

Targeting of XJB-5-131 to Mitochondria Suppresses Oxidative DNA Damage and Motor Decline in a Mouse Model of Huntington’s Disease

Xun, Z., Rivera, S., Ayala‐Peña, S., Lim, J. I., Budworth, H., Skoda, E. M., Robbins, P. D., Niedernhofer, L. J., Wipf, P., & McMurray, C. T. (2012) · Cell Reports · doi:10.1016/j.celrep.2012.10.001 · Cited by 150 · see citing works

Clinical Utility and Analytical Challenges in Measurement of Cerebrospinal Fluid Amyloid-β1–42 and τ Proteins as Alzheimer Disease Biomarkers

Kang, J., Korecka, M., Toledo, J. B., Trojanowski, J. Q., & Shaw, L. M. J. (2013) · Clinical Chemistry · doi:10.1373/clinchem.2013.202937 · Cited by 146 · see citing works

Biomarkers in Alzheimer's disease drug development

Blennow, K. (2010) · Nature Medicine · doi:10.1038/nm.2221 · Cited by 145 · see citing works

Inadequate supply of vitamins and DHA in the elderly: Implications for brain aging and Alzheimer-type dementia

Mohajeri, M. H., Troesch, B., & Weber, P. (2015) · Nutrition · doi:10.1016/j.nut.2014.06.016 · Cited by 141 · see citing works

Current and emerging avenues for Alzheimer's disease drug targets

Loera‐Valencia, R., Cedazo-Mı́nguez, Á., Kenigsberg, P.-A., Page, G., Duarte, A. I., Giusti, P., Zusso, M., Robert, P. H., Frisoni, G. B., Cattaneo, A., et al. (2019) · Journal of Internal Medicine · doi:10.1111/joim.12959 · Cited by 139 · see citing works

Drug development status for Alzheimer’s disease: present scenario

Misra, S., & Medhi, B. (2013) · Neurological Sciences · doi:10.1007/s10072-013-1316-x · Cited by 31 · see citing works

Alzheimer's Disease: A Review

Poonam Dapke* Ms. Sonali Kalam, D. G. S. (2023) · Zenodo (CERN European Organization for Nuclear Research) · doi:10.5281/zenodo.10130202

Current therapeutics for Alzheimer’s disease and clinical trials

Xiao, D., & Zhang, C. (2024) · Exploration of Neuroscience · doi:10.37349/en.2024.00048 · Cited by 30 · see citing works

In search of Alzheimer’s disease treatment methods: trends of clinical trials

Pakulaite-Kazliene, G., Regelskytė, V., Audronytė, E., Kuzmickienė, J., & Kaubrys, G. (2018) · Neurologijos seminarai · doi:10.29014/ns.2018.03 · Cited by 1 · see citing works

The Development of Pharmacological Therapies for Alzheimer’s Disease

Ping, L., Sun, J., Cheng, Q., Yang, Y., Cordato, D. J., & Gao, J. (2021) · Neurology and Therapy · doi:10.1007/s40120-021-00282-z · Cited by 16 · see citing works